Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Iterum Therapeutics (Nasdaq: ITRM), a company focused on developing next-generation antibiotics, has granted a non-statutory share option to its new Chief Commercial Officer, Christine Coyne. The option allows for the purchase of 200,000 ordinary shares at an exercise price of $0.97 per share.
The share option, granted on July 1, 2025, has a 10-year term and follows a four-year vesting schedule: 25% vests after the first year, with the remainder vesting monthly over 36 months. This grant was made as an inducement award under Nasdaq Listing Rule 5635(c)(4) and is part of Ms. Coyne's employment compensation package.
Iterum Therapeutics (Nasdaq: ITRM), un'azienda specializzata nello sviluppo di antibiotici di nuova generazione, ha concesso un'opzione azionaria non statutaria alla sua nuova Chief Commercial Officer, Christine Coyne. L'opzione consente l'acquisto di 200.000 azioni ordinarie a un prezzo di esercizio di 0,97 $ per azione.
L'opzione, concessa il 1掳 luglio 2025, ha una durata di 10 anni e prevede un piano di maturazione quadriennale: il 25% matura dopo il primo anno, mentre il restante 75% matura mensilmente nei successivi 36 mesi. Questa concessione 猫 stata effettuata come premio di incentivazione ai sensi della Regola 5635(c)(4) del Nasdaq ed 猫 parte del pacchetto retributivo di Ms. Coyne.
Iterum Therapeutics (Nasdaq: ITRM), una empresa dedicada al desarrollo de antibi贸ticos de pr贸xima generaci贸n, ha otorgado una opci贸n sobre acciones no estatutaria a su nueva Directora Comercial, Christine Coyne. La opci贸n permite la compra de 200,000 acciones ordinarias a un precio de ejercicio de $0.97 por acci贸n.
La opci贸n sobre acciones, concedida el 1 de julio de 2025, tiene un plazo de 10 a帽os y sigue un calendario de adquisici贸n de derechos de cuatro a帽os: el 25% se adquiere tras el primer a帽o, y el resto se adquiere mensualmente durante los siguientes 36 meses. Esta concesi贸n se realiz贸 como un premio de incentivo bajo la Regla 5635(c)(4) de Nasdaq y forma parte del paquete de compensaci贸n laboral de la Sra. Coyne.
Iterum Therapeutics (雮橃姢雼�: ITRM)電� 彀劯雽� 頃儩鞝� 臧滊皽鞐� 欤茧牓頃橂姅 須岇偓搿�, 靸堧鞖� 斓滉碃 靸侅梾 毂呾瀯鞛愳澑 Christine Coyne鞐愱矊 牍勲矔鞝� 欤检嫕毵れ垬靹犿儩甓岇潉 攵�鞐枅鞀惦媹雼�. 鞚� 鞓奠厴鞚� 200,000 氤错喌欤�毳� 欤茧嫻 $0.97鞚� 頄夓偓臧�瓴╈溂搿� 甑Г頃� 靾� 鞛堧姅 甓岆Μ毳� 鞝滉车頃╇媹雼�.
2025雲� 7鞗� 1鞚检棎 攵�鞐悳 鞚� 欤检嫕毵れ垬靹犿儩甓岇潃 10雲勳潣 旮瓣皠鞚� 臧�歆�氅� 4雲勱皠鞚� 氩犾姢韺� 鞚检爼鞐� 霐半澕 鞖挫榿霅╇媹雼�: 觳� 頃� 頉� 25%臧� 氩犾姢韺呺悩氅�, 雮橂ǜ歆�電� 36臧滌洈 霃欖晥 毵れ洈 氩犾姢韺呺惄雼堧嫟. 鞚� 攵�鞐姅 Nasdaq 靸侅灔攴滌爼 5635(c)(4)鞐� 霐半ジ 鞙犾澑靸侅溂搿� 鞚措（鞏挫鞙茧┌, Coyne 鞌潣 瓿犾毄 氤挫儊 韺偆歆�鞚� 鞚茧秬鞛呺媹雼�.
Iterum Therapeutics (Nasdaq : ITRM), une soci茅t茅 sp茅cialis茅e dans le d茅veloppement d'antibiotiques de nouvelle g茅n茅ration, a accord茅 une option d'achat d'actions non statutaire 脿 sa nouvelle Directrice Commerciale, Christine Coyne. Cette option permet l'achat de 200 000 actions ordinaires 脿 un prix d'exercice de 0,97 $ par action.
L'option, accord茅e le 1er juillet 2025, a une dur茅e de 10 ans et suit un calendrier d'acquisition de droits sur quatre ans : 25 % des actions sont acquises apr猫s la premi猫re ann茅e, le reste 茅tant acquis mensuellement sur 36 mois. Cette attribution a 茅t茅 faite en tant que prime d'incitation conform茅ment 脿 la r猫gle 5635(c)(4) du Nasdaq et fait partie du package de r茅mun茅ration de Mme Coyne.
Iterum Therapeutics (Nasdaq: ITRM), ein Unternehmen, das sich auf die Entwicklung von Antibiotika der n盲chsten Generation spezialisiert hat, hat seiner neuen Chief Commercial Officer, Christine Coyne, eine nicht-statutory Aktienoption gew盲hrt. Die Option erm枚glicht den Kauf von 200.000 Stammaktien zu einem Aus眉bungspreis von 0,97 $ pro Aktie.
Die am 1. Juli 2025 gew盲hrte Aktienoption hat eine Laufzeit von 10 Jahren und folgt einem vierj盲hrigen Vesting-Plan: 25 % werden nach dem ersten Jahr f盲llig, der Rest wird im Laufe von 36 Monaten monatlich vestet. Diese Gew盲hrung erfolgte als Anreiz gem盲脽 Nasdaq Listing Rule 5635(c)(4) und ist Teil von Frau Coynes Verg眉tungspaket.
- None.
- None.
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (鈥淚terum鈥� or the 鈥淐ompany鈥�), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum鈥檚 newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation.
The share option was granted effective July 1, 2025, with an exercise price of
About Iterum Therapeutics plc
Iterum is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH鈩� (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women with limited or no alternative oral antibacterial treatment options by the FDA and has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications. For more information, please visit .
About ORLYNVAH鈩�
ORLYNVAH鈩� is a novel oral penem antibiotic for the treatment of uUTIs. ORLYNVAH鈩� possesses potent activity against species of Enterobacterales including those that encode extended spectrum beta-lactamase (ESBL) or AmpC-type beta-lactamases that confer resistance to third generation cephalosporins.
Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
FAQ
What stock options did Iterum Therapeutics (ITRM) grant to its new Chief Commercial Officer?
Who is the new Chief Commercial Officer at Iterum Therapeutics (ITRM)?
What is the vesting schedule for ITRM's inducement grant to Christine Coyne?
What is Nasdaq Listing Rule 5635(c)(4) under which ITRM granted the options?
